Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2012, Article ID 915375, 17 pages
http://dx.doi.org/10.1155/2012/915375
Review Article

Combination Drug Delivery Approaches in Metastatic Breast Cancer

1Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Baltimore, MD 21201, USA
2University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA

Received 22 November 2011; Revised 2 February 2012; Accepted 7 February 2012

Academic Editor: Nevio Picci

Copyright © 2012 Jun H. Lee and Anjan Nan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. A. C. Greenberg, G. N. Hortobagyi, T. L. Smith, L. D. Ziegler, D. K. Frye, and A. U. Buzdar, “Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 8, pp. 2197–2205, 1996. View at Google Scholar · View at Scopus
  3. O. Pagani, E. Senkus, W. Wood et al., “International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?” Journal of the National Cancer Institute, vol. 102, no. 7, pp. 456–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. J Horner, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2008.
  5. M. Stockler, N. R. C. Wilcken, D. Ghersi, and R. J. Simes, “Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer,” Cancer Treatment Reviews, vol. 26, no. 3, pp. 151–168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Geels, E. Eisenhauer, A. Bezjak, B. Zee, and A. Day, “Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 18, no. 12, pp. 2395–2405, 2000. View at Google Scholar · View at Scopus
  7. K. L. Maughan, M. A. Lutterbie, and P. S. Ham, “Treatment of breast cancer,” American Family Physician, vol. 81, no. 11, pp. 1339–1346, 2010. View at Google Scholar
  8. D. Osoba, “Health-related quality of life as a treatment endpoint in metastatic breast cancer,” The Canadian journal of oncology, vol. 5, supplement 1, pp. 47–53, 1995. View at Google Scholar
  9. “randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia,” Journal of Clinical Oncology, vol. 4, no. 2, pp. 186–193, 1986.
  10. R. Fossati, C. Confalonieri, V. Torri et al., “Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3439–3460, 1998. View at Google Scholar · View at Scopus
  11. J. Schwartz, “Current combination chemotherapy regimens for metastatic breast cancer,” American Journal of Health-System Pharmacy, vol. 66, no. 6, pp. S3–S8, 2009. View at Google Scholar · View at Scopus
  12. R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nature Reviews Cancer, vol. 6, no. 9, pp. 688–701, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Duncan, M. J. Vicent, F. Greco, and R. I. Nicholson, “Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer,” Endocrine-Related Cancer, vol. 12, no. 1, pp. S189–S199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, and O. C. Farokhzad, “Nanoparticles in medicine: therapeutic applications and developments,” Clinical Pharmacology and Therapeutics, vol. 83, no. 5, pp. 761–769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review,” Journal of Controlled Release, vol. 65, no. 1-2, pp. 271–284, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Minko, P. Kopečková, and J. Kopeček, “Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma,” International Journal of Cancer, vol. 86, no. 1, pp. 108–117, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Moreno-Aspitia and E. A. Perez, “Treatment options for breast cancer resistant to anthracycline and taxane,” Mayo Clinic Proceedings, vol. 84, no. 6, pp. 533–545, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Bria, D. Giannarelli, A. Felici et al., “Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma: pooled analysis of 2805 patients,” Cancer, vol. 103, no. 4, pp. 672–679, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Blomqvist, I. Elomaa, P. Rissanen, P. Hietanen, K. Nevasaari, and L. Helle, “Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration,” Journal of Clinical Oncology, vol. 11, no. 3, pp. 467–473, 1993. View at Google Scholar · View at Scopus
  20. H. T. Mouridsen, “Systemic therapy of advanced breast cancer,” Drugs, vol. 44, no. 4, pp. 17–28, 1992. View at Google Scholar · View at Scopus
  21. L. Livi, I. Meattini, C. D. L. Cardillo et al., “Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis,” Tumori, vol. 95, no. 4, pp. 422–426, 2009. View at Google Scholar · View at Scopus
  22. J. Jassem, T. Pieńkowski, A. Pluzanska et al., “Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial,” Journal of Clinical Oncology, vol. 19, no. 6, pp. 1707–1715, 2001. View at Google Scholar
  23. J. Bonneterre, “A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients,” Journal of Clinical Oncology, vol. 9, no. 2, pp. 305–312, 1991. View at Google Scholar
  24. H. Joensuu, K. Holli, M. Heikkinen et al., “Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial,” Journal of Clinical Oncology, vol. 16, no. 12, pp. 3720–3730, 1998. View at Google Scholar · View at Scopus
  25. K. S. Albain, S. M. Nag, G. Calderillo-Ruiz et al., “Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment,” Journal of Clinical Oncology, vol. 26, no. 24, pp. 3950–3957, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Pérez-Tomás, “Multidrug resistance: retrospect and prospects in anti-cancer drug treatment,” Current Medicinal Chemistry, vol. 13, no. 16, pp. 1859–1876, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. E. S. Thomas, H. L. Gomez, R. K. Li et al., “Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment,” Journal of Clinical Oncology, vol. 25, no. 33, pp. 5210–5217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Burzykowski, M. Buyse, M. J. Piccart-Gebhart et al., “Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 1987–1992, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Chan, G. Romieu, J. Huober et al., “Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1753–1760, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. O'Shaughnessy, D. Miles, S. Vukelia et al., “Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2812–2823, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Bonadonna, P. Valagussa, A. Moliterni, M. Zambetti, and C. Brambilla, “Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up,” New England Journal of Medicine, vol. 332, no. 14, pp. 901–906, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. J. D. Hainsworth, “Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxel,” European Journal of Cancer Care, vol. 6, no. 4, pp. 4–9, 1997. View at Google Scholar · View at Scopus
  33. S. P. Ackland, A. Anton, G. P. Breitbach et al., “Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 943–953, 2001. View at Google Scholar · View at Scopus
  34. A. Azzariti, L. Porcelli, G. M. Simone et al., “Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 2, pp. 335–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Hasnaoui, D. Blanchard, C. Willem, M. J. Loirat, and P. Lambin, “Production and properties of monoclonal antibodies against human IgG isotypes,” Hybridoma, vol. 15, no. 5, pp. 351–358, 1996. View at Google Scholar · View at Scopus
  36. C. A. Hudis, “Trastuzumab—mechanism of action and use in clinical practice,” New England Journal of Medicine, vol. 357, no. 1, pp. 39–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Cobleigh, V. K. Langmuir, G. W. Sledge et al., “A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer,” Seminars in Oncology, vol. 30, no. 5 , supplement 16, pp. 117–124, 2003. View at Google Scholar
  38. J. Baselga, J. M. Trigo, J. Bourhis et al., “Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5568–5577, 2005. View at Publisher · View at Google Scholar
  39. C. A. Hudis and L. Gianni, “Triple-negative breast cancer: an unmet medical need,” The Oncologist, vol. 16 , supplement 1, pp. 1–11, 2011. View at Google Scholar
  40. F. Cappuzzo, M. Varella-Garcia, G. Finocchiaro et al., “Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients,” British Journal of Cancer, vol. 99, no. 1, pp. 83–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Marty, F. Cognetti, D. Maraninchi et al., “Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group,” Journal of Clinical Oncology, vol. 23, no. 19, pp. 4265–4274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Robert, B. Leyland-Jones, L. Asmar et al., “Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2—overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2786–2792, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Bartsch, C. Wenzel, G. Altorjai et al., “Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3853–3858, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer,” New England Journal of Medicine, vol. 357, no. 26, pp. 2666–2676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Cameron, M. Casey, C. Oliva, B. Newstat, B. Imwalle, and C. E. Geyer, “Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial,” Oncologist, vol. 15, no. 9, pp. 924–934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Di Leo, H. L. Gomez, Z. Aziz et al., “Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer,” Journal of Clinical Oncology, vol. 26, no. 34, pp. 5544–5552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Moy and P. E. Goss, “Lapatinib-associated toxicity and practical management recommendations,” Oncologist, vol. 12, no. 7, pp. 756–765, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. F. O. Ademuyiwa and K. D. Miller, “Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer,” Clinical Breast Cancer, vol. 8, no. 4, pp. S151–S156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. U. Gatzemeier, A. Pluzanska, A. Szczesna et al., “Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1545–1552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. J. O'Shaughnessy, C. Osborne, J. E. Pippen et al., “Iniparib plus chemotherapy in metastatic triple-negative breast cancer,” New England Journal of Medicine, vol. 364, no. 3, pp. 205–214, 2011. View at Publisher · View at Google Scholar
  51. L. T. Gien and H. J. Mackay, “The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer,” Journal of Oncology, vol. 2010, Article ID 151750, 6 pages, 2010. View at Publisher · View at Google Scholar
  52. K. L. Blackwell, H. J. Burstein, A. M. Storniolo et al., “Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1124–1130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Y. S. Yip, L. A. Tse, E. Y. Y. Ong, and L. W. C. Chow, “Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review,” Anti-Cancer Drugs, vol. 21, no. 5, pp. 487–493, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. H. J. Burstein, A. D. Elias, H. S. Rugo et al., “Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1810–1816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. R. K. Jain, D. G. Duda, J. W. Clark, and J. S. Loeffler, “Lessons from phase III clinical trials on anti-VEGF therapy for cancer,” Nature Clinical Practice Oncology, vol. 3, no. 1, pp. 24–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. C. J. Lord and A. Ashworth, “Targeted therapy for cancer using PARP inhibitors,” Current Opinion in Pharmacology, vol. 8, no. 4, pp. 363–369, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Farmer, H. McCabe, C. J. Lord et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy,” Nature, vol. 434, no. 7035, pp. 917–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Drew, E. A. Mulligan, W.-T. Vong et al., “Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2,” Journal of the National Cancer Institute, vol. 103, no. 4, pp. 334–346, 2011. View at Publisher · View at Google Scholar
  59. G. Tomasello, E. de Azambuja, P. Dinh, N. Snoj, and M. Piccart-Gebhart, “Jumping higher: Is it still possible? The ALTTO trial challenge,” Expert Review of Anticancer Therapy, vol. 8, no. 12, pp. 1883–1890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Moy and P. E. Goss, “Lapatinib: current status and future directions in breast cancer,” Oncologist, vol. 11, no. 10, pp. 1047–1057, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. A. M. Storniolo, M. D. Pegram, B. Overmoyer et al., “Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer,” Journal of Clinical Oncology, vol. 26, no. 20, pp. 3317–3323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. D. F. Emerich and C. G. Thanos, “Targeted nanoparticle-based drug delivery and diagnosis,” Journal of Drug Targeting, vol. 15, no. 3, pp. 163–183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Greco, M. J. Vicent, S. Gee et al., “Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells,” Journal of Controlled Release, vol. 117, no. 1, pp. 28–39, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. V. P. Torchilin, “Recent advances with liposomes as pharmaceutical carriers,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 145–160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. M. C. Woodle, “Controlling liposome blood clearance by surface-grafted polymers,” Advanced Drug Delivery Reviews, vol. 32, no. 1-2, pp. 139–152, 1998. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Zucker, A. V. Andriyanov, A. Steiner, U. Raviv, and Y. Barenholz, “Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy,” Journal of Controlled Release . In press.
  67. S. M. Lee, T. V. O'Halloran, and S. T. Nguyen, “Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy,” Journal of the American Chemical Society, vol. 132, no. 48, pp. 17130–17138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Sapra and T. M. Allenz, “Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs,” Cancer Research, vol. 62, no. 24, pp. 7190–7194, 2002. View at Google Scholar · View at Scopus
  69. J. Wu, Y. Lu, A. Lee et al., “Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 10, no. 3, pp. 350–357, 2007. View at Google Scholar · View at Scopus
  70. L. D. Mayer, T. O. Harasym, P. G. Tardi et al., “Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice,” Molecular Cancer Therapeutics, vol. 5, no. 7, pp. 1854–1863, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. E. J. Feldman, J. E. Lancet, J. E. Kolitz et al., “First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia,” Journal of Clinical Oncology, vol. 29, no. 8, pp. 979–985, 2011. View at Publisher · View at Google Scholar
  72. G. Batist, K. A. Gelmon, K. N. Chi et al., “Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors,” Clinical Cancer Research, vol. 15, no. 2, pp. 692–700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Dicko, A. A. Frazier, B. D. Liboiron et al., “Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes,” Pharmaceutical Research, vol. 25, no. 7, pp. 1702–1713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. P. G. Tardi, N. Dos Santos, T. O. Harasym et al., “Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2266–2275, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. M. -Y. Wong and G. N.C. Chiu, “Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model,” Nanomedicine, vol. 7, no. 6, pp. 834–840, 2011. View at Publisher · View at Google Scholar
  76. Y. Chen, S. R. Bathula, J. Li, and L. Huang, “Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer,” Journal of Biological Chemistry, vol. 285, no. 29, pp. 22639–22650, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. V. Agrawal, M. K. Paul, and A. K. Mukhopadhyay, “6-Mercaptopurine and daunorubicin double drug liposomes–preparation, drug-drug interaction and characterization,” Journal of Liposome Research, vol. 15, no. 3-4, pp. 141–155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. Y. Ren, C. S. Kang, X. B. Yuan et al., “Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro,” Journal of Biomaterials Science, vol. 21, no. 3, pp. 303–314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. I. -H. Lee, S. An, M. K. Yu, H. -K. Kwon, S. -H. Im, and S. Jon, “Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates,” Journal of Controlled Release, vol. 155, no. 3, pp. 435–441, 2011. View at Publisher · View at Google Scholar
  80. C. Clementi, K. Miller, A. Mero, R. Satchi-Fainaro, and G. Pasut, “Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms,” Molecular Pharmaceutics, vol. 8, no. 4, pp. 1063–1072, 2011. View at Publisher · View at Google Scholar
  81. T. L. Kaneshiro and Z. R. Lu, “Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier,” Biomaterials, vol. 30, no. 29, pp. 5660–5666, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. R. K. Tekade, T. Dutta, A. Tyagi, A. C. Bharti, B. C. Das, and N. K. Jain, “Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy,” Journal of Drug Targeting, vol. 16, no. 10, pp. 758–772, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. L. Milane, Z.-F. Duan, and M. Amiji, “Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer,” Nanomedicine, vol. 7, no. 4, pp. 435–444, 2011. View at Publisher · View at Google Scholar
  84. H. Wang, Y. Zhao, Y. Wu et al., “Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles,” Biomaterials, vol. 32, no. 32, pp. 8281–8290, 2011. View at Publisher · View at Google Scholar
  85. H. C. Shin, A. W. G. Alani, D. A. Rao, N. C. Rockich, and G. S. Kwon, “Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs,” Journal of Controlled Release, vol. 140, no. 3, pp. 294–300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Yang, Y. Wang, Z. Li et al., “Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature,” Nanomedicine, vol. 8, no. 1, pp. 81–92, 2012. View at Publisher · View at Google Scholar
  87. C. Zhu, S. Jung, S. Luo et al., “Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers,” Biomaterials, vol. 31, no. 8, pp. 2408–2416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Sengupta, D. Eavarone, I. Capila et al., “Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system,” Nature, vol. 436, no. 7050, pp. 568–572, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. U. Katragadda, Q. Teng, B. M. Rayaprolu, T. Chandran, and C. Tan, “Multi-drug delivery to tumor cells via micellar nanocarriers,” International Journal of Pharmaceutics, vol. 419, no. 1-2, pp. 281–286, 2011. View at Publisher · View at Google Scholar
  90. Y. Wang, S. Gao, W. H. Ye, H. S. Yoon, and Y. Y. Yang, “Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer,” Nature Materials, vol. 5, no. 10, pp. 791–796, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Bae, T. A. Diezi, A. Zhao, and G. S. Kwon, “Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents,” Journal of Controlled Release, vol. 122, no. 3, pp. 324–330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. X. R. Song, Y. Zheng, G. He et al., “Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma,” Journal of Pharmaceutical Sciences, vol. 99, no. 12, pp. 4874–4879, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Emilienne Soma, C. Dubernet, D. Bentolila, S. Benita, and P. Couvreur, “Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles,” Biomaterials, vol. 21, no. 1, pp. 1–7, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. F. Greco, M. J. Vicent, N. A. Penning, R. I. Nicholson, and R. Duncan, “HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines,” Journal of Drug Targeting, vol. 13, no. 8-9, pp. 459–470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Lammers, V. Subr, K. Ulbrich et al., “Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers,” Biomaterials, vol. 30, no. 20, pp. 3466–3475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Krakovičová, T. Etrych, and K. Ulbrich, “HPMA-based polymer conjugates with drug combination,” European Journal of Pharmaceutical Sciences, vol. 37, no. 3-4, pp. 405–412, 2009. View at Publisher · View at Google Scholar
  97. E. Segal, H. Pan, P. Ofek et al., “Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics,” PLoS ONE, vol. 4, no. 4, 2009. View at Publisher · View at Google Scholar
  98. K. Miller, R. Erez, E. Segal, D. Shabat, and R. Satchi-Fainaro, “Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate,” Angewandte Chemie, vol. 48, no. 16, pp. 2949–2954, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Pasut, F. Greco, A. Mero et al., “Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6499–6502, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Santucci, A. Mencarelli, B. Renga et al., “Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin,” FASEB Journal, vol. 20, no. 6, pp. 765–767, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Santucci, A. Mencarelli, B. Renga et al., “Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice,” Anti-Cancer Drugs, vol. 18, no. 9, pp. 1081–1091, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Chandna, J. J. Khandare, E. Ber, L. Rodriguez-Rodriguez, and T. Minko, “Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers,” Pharmaceutical Research, vol. 27, no. 11, pp. 2296–2306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. J. H. Lee, G. Sabnis, A. Brodie, and A. Nan, “In vitro evaluation of HER2 targeted N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates in combination treatment with tyrosine kinase inhibitor (PKI-166),” in Proceedings of the 102nd Annual Meeting of the AACR, Abstract no 3230, Orlando, Fla, USA, 2011.
  104. D. A. Tomalia, L. A. Reyna, and S. Svenson, “Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging,” Biochemical Society Transactions, vol. 35, no. 1, pp. 61–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Kopecek and H. Bazilova, “Poly[N-(2-hydroxypropyl)methacrylamide]-I. Radical polymerization and copolymerization,” European Polymer Journal, vol. 9, no. 1, pp. 7–14, 1973. View at Google Scholar · View at Scopus
  106. R. Duncan, “Biological effects of soluble synthetic polymers as drug carriers,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, no. 4, pp. 281–310, 1985. View at Google Scholar · View at Scopus
  107. R. Duncun and F. Spreafico, “Polymer conjugates. Pharmacokinetic considerations for design and development,” Clinical Pharmacokinetics, vol. 27, no. 4, pp. 290–306, 1994. View at Google Scholar · View at Scopus
  108. C. F. Verschraegen, K. Skubitz, A. Daud et al., “A phase i and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 5, pp. 903–910, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Dipetrillo, L. Milas, D. Evans et al., “Paclitaxel Poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study,” American Journal of Clinical Oncology, vol. 29, no. 4, pp. 376–379, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. J. G. Shiah, Y. Sun, P. Kopečková, C. M. Peterson, R. C. Straight, and J. Kopeček, “Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates,” Journal of Controlled Release, vol. 74, no. 1–3, pp. 249–253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Fang, T. Sawa, T. Akaike, K. Greish, and H. Maeda, “Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin,” International Journal of Cancer, vol. 109, no. 1, pp. 1–8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. F. Canal, J. Sanchis, and M. J. Vicent, “Polymer-drug conjugates as nano-sized medicines,” Current Opinion in Biotechnology, vol. 22, no. 6, pp. 894–900, 2011. View at Publisher · View at Google Scholar
  113. F. Greco and M. J. Vicent, “Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines,” Advanced Drug Delivery Reviews, vol. 61, no. 13, pp. 1203–1213, 2009. View at Publisher · View at Google Scholar
  114. J. Kopeček and P. Kopečková, “HPMA copolymers: origins, early developments, present, and future,” Advanced Drug Delivery Reviews, vol. 62, no. 2, pp. 122–149, 2010. View at Publisher · View at Google Scholar